Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
Book a demo for a pilot project
BeiGene, a leading global biotechnology company often referred to simply as BeiGene, is at the forefront of pharmaceutical preparation manufacturing. Headquartered in China, with significant operational presences across North America, Europe, and Asia, BeiGene is dedicated to developing innovative oncology medicines worldwide.
Founded in 2010, BeiGene has rapidly evolved, marked by key milestones in clinical development and global commercialisation of its diverse oncology pipeline. Their core offering includes cutting-edge therapies for various cancers, distinguishing themselves through a commitment to impactful, patient-centric drug development.
BeiGene has carved out a significant market position, evidenced by its robust portfolio of approved and late-stage clinical assets. They are recognised for their innovative approach to discovering novel molecular entities and expanding access to high-quality medicines globally.
+5 vs industry average
Beigene’s score of 47 is higher than 57% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Pharmaceutical Preparation Manufacturing is among the most carbon-intensive industries
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Scope 3 accounts for ••• of total emissions.
In 2025, BeiGene reported total carbon emissions of approximately 745,000,000 kg CO2e, comprising 11,539,000 kg CO2e from Scope 1, 102,622,000 kg CO2e from Scope 2, and 627,386,000 kg CO2e from Scope 3 emissions. This data reflects a comprehensive approach to emissions reporting, including all relevant scopes.
The company has set ambitious climate commitments, aiming to reduce its Scope 1 and Scope 2 emissions to near zero by 2025. Additionally, BeiGene targets a 30% reduction in both Scope 1 and Scope 2 emissions by 2030, using 2020 as the baseline year. Furthermore, they plan to achieve a 25% reduction in Scope 1 and 2 emissions per unit of internally manufactured commercial products by 2026, with 2021 as the baseline.
These initiatives demonstrate BeiGene's commitment to sustainability and align with industry standards for climate action. The emissions data and reduction targets are sourced directly from BeiGene, Ltd., ensuring accuracy and relevance in their climate strategy.
2025
Near-zero scope 1 & 2
Target to achieve near-zero emissions for direct operations and purchased energy
2030
62% reduction in total GHG
Vs 2019 baseline. Validated by SBTi. Includes full supply chain.
2040
50% reduction in Scope 3 intensity
Across purchased goods and services and logistics.
Showing SBTi-validated targets only. Sign up or sign in to see all disclosed climate targets.
No scope 3 category breakdown has been disclosed yet.


PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more